Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2008 Mar 1.

Published in final edited form as: J Mol Cell Cardiol. 2006 Dec 29;42(3):653–661. doi: 10.1016/j.yjmcc.2006.12.011

Fig 1 — A. ARVM were treated with isoproterenol (ISO; 10 μM) for 15 min (15’), 30 min (30’), 1 h, 3 h, 6 h and 24 h. Activity of GSK-3β was measured using immune-complex kinase assay as described in the methods. The results are expressed as fold change in activity vs. control (CTL). *p<0.05 vs. CTL; n=4–10. Addition of LiCl (1 mM) in the reaction mix (B) or infection with KM-GSK (C) inhibits β-AR stimulated increases in GSK-3β activity. *p<0.05 vs. control (CTL/GFP); n=3–7; #p<0.05 vs. ISO/GFP+ISO; n=3. D. ARVM were treated with ISO for 15 min (15’), 3 h, 6 h and 24 h. Cell lysates were analyzed by western blot using phospho-specific (ser⁹) GSK-3β antibodies, while activity of GSK-3β was measured using immune-complex kinase assay. *p<0.05 vs. CTL; n=3–10.

Fig 1 — A. ARVM were treated with isoproterenol (ISO; 10 μM) for 15 min (15’), 30 min (30’), 1 h, 3 h, 6 h and 24 h. Activity of GSK-3β was measured using immune-complex kinase assay as described in the methods. The results are expressed as fold change in activity vs. control (CTL). *p<0.05 vs. CTL; n=4–10. Addition of LiCl (1 mM) in the reaction mix (B) or infection with KM-GSK (C) inhibits β-AR stimulated increases in GSK-3β activity. *p<0.05 vs. control (CTL/GFP); n=3–7; #p<0.05 vs. ISO/GFP+ISO; n=3. D. ARVM were treated with ISO for 15 min (15’), 3 h, 6 h and 24 h. Cell lysates were analyzed by western blot using phospho-specific (ser⁹) GSK-3β antibodies, while activity of GSK-3β was measured using immune-complex kinase assay. *p<0.05 vs. CTL; n=3–10.